We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Rapid Identification of Pathogens Causing Bacterial Septicemia

By LabMedica International staff writers
Posted on 24 Aug 2010
A molecular based test is now available that will simultaneously identify three Gram-negative bacteria directly from positive blood cultures in less than 90 minutes.

A three-color multiplex assay allows for the identification of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa from positive blood cultures.
Smears of blood cultures are heat fixed onto microscope slides, a drop of GNR Traffic Light peptide nucleic acid fluorescence in situ hybridization (PNA FISH) probe is added to the smear and then hybridized at 55 °C for 30 minutes. More...


The GNR Traffic Light PNA probe is mixture of a fluorescein-labeled E. coli-specific PNA probe, a fluorescein and tetramethylrhodamine labeled K. pneumoniae-specific
PNA probe and a Texas Red labeled P. aeruginosa-specific PNA probe.

The slides are then washed for 30 minutes at 55 °C. After which the slides are mounted and visualized with a fluorescence microscope with a FITC/Texas Red filter and 60× oil objective. E. coli is identified as green fluorescent cells, K. pneumoniae as yellow and P. aeruginosa as red. The GNR Traffic Light PNA FISH assay is the latest test from AdvanDx (Woburn MA, USA) and is now available in Europe. It is an addition to their easy-to-use, molecular-based PNA FISH diagnostics platform designed to provide rapid, therapy-guiding results enabling clinicians to provide early, effective therapy for patients with Gram-negative bloodstream infections.

Studies show that providing a 24 hours "head start" on appropriate, narrow-spectrum therapy for Gram-negative bloodstream infections may improve clinical outcomes, reduce antibiotic resistance rates, and reduce the incidences of adverse events. GNR Traffic Light PNA FISH will enable microbiology labs to provide clinicians rapid, accurate Gram-negative pathogen identification results in hours, instead of days. Every year, close to 875,000 patients in the USA contract bloodstream infections, leading to over 150,000 deaths. The infection is detected when a culture of the patient's blood turns positive with bacteria or yeast. Rapid and accurate identification of the specific infecting pathogen is crucial to ensure early and appropriate therapy and save patient lives.

Thais T. Johansen, M.B.A., president and CEO of AdvanDx, said, "The GNR Traffic Light PNA FISH test demonstrates AdvanDx's commitment to developing cutting-edge molecular diagnostic products that provide fast results for these serious infections."

Related Links:
AdvanDx


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
See-Saw Rocking Shaker
SH-200D-S-L
New
Giardia Assay
AccuDiag Giardia
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The precision oncology test identifies patients most at risk of undergoing severe toxicity from treatment with 5FU/capecitabine (Photo courtesy of 123RF)

Precision Oncology Test Predicts Patient Toxicity Before Beginning Chemotherapy

5-fluorouracil (5FU) and capecitabine have been cornerstone chemotherapeutic agents for over four decades, effectively treating a variety of cancers. However, 5FU/capecitabine can cause varying degrees... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Mimix Reference Standards are cell-line derived to maintain genomic complexity and mimic patient material across molecular diagnostics workflows (Photo courtesy of Revvity)

New Cancer Testing Standards to Improve Diagnostic Accuracy for Oncology Labs

Accurate diagnosis, including the identification of genomic markers, is essential for determining the most effective cancer treatments for patients. To ensure this, laboratories require reliable reference... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.